anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Irritable Bowel Syndrome(IBS) is a chronic relapsing disorder with unknown etiology characterized by abdominal pain and bowel habit changes without an organic pathology. Pathophysiology is not fully understood, bacterial overgrowth is one of the reasons. Because of that, use of drugs effective on the gut flora has been raised; Rifaximin is one of them. This study investigated the effectiveness of Rifaximin on IBS.

This randomized, double-blinded, controlled study began with 500 patients(144 of them removed because of incompliance). Patients those without organic bowel pathology and whom meet the Rome-III criteria, aged between 19-50 yo were enrolled in the study. Patients with known Rifaximin allergy, lactose intolerance, and those having treated for IBS whit in last 1 month as well as those with alarm symptoms (melena, fever, weight loss, anemia, rectal bleeding) were excluded. After routine biochemistry, blood count, and stool tests, Rifaximin tablet was given to a group as 1200 mg. daily in 3 divided doses, placebo tablet was given to another group in same doses for 10 days. Improvement in symptoms were scored and recorded on 10.day, 3. and 6.week. In addition to descriptive statistical methods(mean±SD), Student's-T and Mann-Whitney U-tests were used for comparison of quantitative data, chi-square and McNemar tests were used for comparison of qualitative data. Significance was accepted if p \<0.05.
1,048,761. Desiccating biological substances. LABORATOIRES DE RECHERCHES EXPERIMENTALES GOULDEN CIE. Dec. 31, 1962 [Nov. 29, 1961], No. 42686/61. Heading A2D. Physically and chemically fragile biological substances are desiccated with their active constituents being left substantially unchanged, by diffusion of water vapour through an artificial vapour-permeable enclosure around the substance consequent upon a removal of water vapour from the medium surrounding the enclosure, under ambient conditions of temperature and pressure, creating a vapour pressure difference as between the interior of the enclosure and the surrounding medium, proportioned quantities of the biological substance being brought into a condition permitting the flow of water vapour into the surrounding medium. When the surrounding medium is a confined atmosphere, the water vapour may be removed by means of a desiccating agent such as silica gel or calcium chloride. Alternatively, the water vapour in a circulating atmosphere may be removed by freezing. Hypophysis glands and other animal tissues, leaves of medicinal plants and other vegetable tissues, pumpkin seeds, and cytochrome and other opotherapic extracts may be desiccated. The enclosures may consist of sterile envelopes of "Cellophane" (Registered Trade Mark), paper bags, unglazed eathernware pots and porous Chamberlan filters.
BACKGROUND: Preserved ratio impaired spirometry (PRISm), defined as decreased forced expiratory volume in the first second in the setting of normal ratio, is associated with an increased risk of respiratory disease and systemic comorbidities. Unlike severe obstructive pulmonary disease, little is known about the impact of PRISm on short-term outcomes in patients undergoing laparoscopic gastrectomy (LG) and its association with small airway dysfunction (SAD).
METHODS: This study enrolled 830 patients who underwent preoperative spirometry and LG between January 2021 and August 2023. Of these, 228 patients were excluded. Participants were categorized into 3 groups based on their baseline lung function, and postoperative outcomes were subsequently analyzed. Potential associations between postoperative outcomes and various clinical variables were examined using univariate and multivariate analyses.
RESULTS: PRISm was identified in 16.6% of the patients, whereas SAD was present in 20.4%. The incidence of postoperative pulmonary complications (PPCs) was notably higher in the SAD group (20.3% vs 9.8%, P = .002) and the PRISm group (28.0% vs 9.8%, P < .001) than the normal group. Among the 3 groups, pneumonia was the most frequently observed PPC. Multivariate analysis revealed that both SAD (odds ratio [OR], 2.34; 95% CI, 1.30-4.22; P = .005) and PRISm (OR, 3.26; 95% CI, 1.80-5.90; P < .001) independently constituted significant risk factors associated with the occurrence of PPCs. Univariate analysis showed that female was a possible risk factor for PPCs in PRISm group.
CONCLUSION: Our study showed that PRISm and SAD were associated with the increased PPCs in patients undergoing LG for gastric cancer.
Although the prevalence of intraventricular hemorrhage (IVH) has remained high, no optimal strategy has been established to prevent it. This study included preterm newborns born at a gestational age of < 32 weeks admitted to the neonatal intensive care unit of a tertiary hospital between January 2013 and June 2022. Infants who had been observed for less than 24 h were excluded. A total of 14 features from time-series data after birth to IVH diagnosis were chosen for model development using an automated machine-learning method. The average F1 scores and area under the receiver operating characteristic curve (AUROC) were used as indicators for comparing the models. We analyzed 778 preterm newborns (79 with IVH, 10.2%; 699 with no IVH, 89.8%) with a median gestational age of 29.4 weeks and birth weight of 1180 g. Model development was performed using data from 748 infants after applying the exclusion criteria. The Extra Trees Classifier model showed the best performance with an average F1 score of 0.93 and an AUROC of 0.999. We developed a model for identifying IVH with excellent accuracy. Further research is needed to recognize high-risk infants in real time.
The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.
The present invention generally relates to the transdermal delivery of substances, e.g., for warming skin. Some aspects of the invention are generally directed to formulations that are able to deliver warming sensations to the skin to the skin within seconds, as opposed to minutes as in certain prior art formulations. In some embodiments, the composition may include warming agents, such as vanillyl butyl ether, which have an onset time of less than 1 minute, in addition to more longer-term warming agents such as oleoresin of capsicum. Other components, such as menthoxypropanediol, may be used in some cases, e.g., to provide a cooling sensation in addition to the warming effects of the warming agents. Surprisingly, this may enhance the warming effect of the warming agent. In addition, in some cases, the formulation may contain a nitric oxide donor, such as L-arginine, which may increase blood flow in the skin, and/O or a high salt environment to facilitate delivery into the skin.
Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis, transmitted naturally from rodent reservoirs to humans via fleas. Human disease may also result from contact with blood or tissues of infected animals or exposure to aerosolized droplets containing bacteria. Pneumonic plague is typically diagnosed in humans with with high mortality. It has a long history for plague as an agent of biowarfare, and pose a serious threat to international security. In human history, there were three outbreaks of plague all over the world, about 200 million people died from the disease. The increasing trend of plague epidemic in recent years, some regions and countries in the world still has the outbreak of the plague. It implied that safety and safe and effective vaccine is urgently to developing.

Althought the killed whole-cell plague vaccine and live attenuated vaccine has been licensed, these vaccines cause significant adverse reactions, including fever, headache, malaise, lymphadenopathy, erythema and induration at the injection site with high degree of immune variability. They are rarely used today because of toxicities, limited evidence for efficacy to prevent plague, and limited commercial availability. Based on the researches in the last twenty years, it have focused on recombinant subunit vaccines which were formed F1 and V antigens as the main composition provide greater protection than vaccines comprised of either subunit alone. In the primary phase 2a clinical trial, 30μg formulation showed a stronger and sustained immune response. This study was aim to exploring the safety and immunogenicity of a new type plague subunit vaccine which comprised 30μg natural F1 antigen and 30μg recombined V antigen (F1+rV) in two immunization regimens.
Meropenem administered intravenously once daily over 6 hours plus amoxicillin/clavulanate 2 x 1000/62.5 mg once daily orally plus pyrazinamide 20-30 mg/kg orally once daily. All study treatments will be administered for 14 consecutive days.
PURPOSE: An injection formulation containing poloxamer 407 and poloxamer 188 is provided to extend a cellular interval maintaining time and to enable easy injection and manipulation, thereby being used in various fields such as tissue cushion or tissue detachment. CONSTITUTION: An injection formulation is injected to a tissue for enlarging the interval between cells. The injection formulation contains poloxamer 407 and poloxamer 188. The injection formulation contains less than 15 wt% of a mixture of poloxamer 407 and poloxamer 188. The injection formulation contains less than 10 wt% of poloxamer 407. A method for enlarging the interval between cells comprises the step of injecting a injection solution into an isolated tissue. [Reference numerals] (AA) Poloxamer total weight 20%; (BB) Viscosity (p); (CC) Temperature (°C)
Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
PROBLEM TO BE SOLVED: To reduce a possibility that identification information is not given to a photographed image or is erroneously given to the photographed image, and to suppress a situation where it is impossible to retrieve a stored photographed image.SOLUTION: An inspection instruction is obtained. It is determined whether the inspection instruction includes identification information for identifying a radiation image photographed in accordance with the inspection instruction. When the identification information is not included, the identification information is obtained. A radiation image photographing device is controlled to photograph a radiation image of a subject in accordance with the inspection instruction, thereby obtaining the photographed radiation image. When the identification information is included, the obtained radiation image is stored in an image management system, which is connected to the radiation image photographing device, while being associated with the identification information included in the obtained inspection instruction. When the identification information is not included, the obtained radiation image is stored in the image management system while being associated with the obtained identification information.
Atorvastatin calcium may cause myopathy (muscle pain, tenderness, or weakness associated with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including atorvastatin. 

Risk Factors for Myopathy

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher atorvastatin calcium dosage [ see Drug Interactions (7.1) and Use in Specific Populations (8.5, 8.6) ].   


Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

Atorvastatin calcium exposure may be increased by drug interactions due to inhibition of cytochrome P450 enzyme 3A4 (CYP3A4) and/or transporters (e.g., breast cancer resistant protein [BCRP], organic anion-transporting polypeptide [OATP1B1/OATP1B3] and P-glycoprotein [P-gp]), resulting in an increased risk of myopathy and rhabdomyolysis. Concomitant use of cyclosporine, gemfibrozil, tipranavir plus ritonavir, or glecaprevir plus pibrentasvir with atorvastatin is not recommended. Atorvastatin calcium dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2.5)]. Cases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir. Consider if the benefit of use of these products outweighs the increased risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)]. 

Concomitant intake of large quantities, more than 1.2 liters daily, of grapefruit juice is not recommended in patients taking atorvastatin calcium [see Drug Interactions (7.1)].

Discontinue atorvastatin calcium tablets if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if atorvastatin calcium tablets are discontinued. Temporarily discontinue atorvastatin calcium tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy). 

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the atorvastatin dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
Described herein are systems and methods for controlling a design and manufacturing process of a user-specific device (e.g., a patient-specific medical device). A method involves receiving, from the requesting entity user-specific information related to a requested device. Based on the information, a list of devices matching user-specific information is determined and displayed for selection by the requesting entity. Based on the information and the selection, a sequence of tasks for design and manufacturing of the user-specific device is generated. Based on the received information and the tasks, a designing entity can generate an interactive digital model of the user-specific device. Based on the interactive model, feedback is received from the requesting entity. Based on the feedback, the interactive digital model and sequence of tasks may be updated. Depending on a location of the requesting entity, the sequence of tasks or devices can be configured to satisfy regulatory compliance.
The feasibility and effectiveness of a family-oriented intervention entitled "AyUDA" will be tested. The AyUDA intervention will provide Latinx families with culturally tailored modules to take control of modifiable behaviors and help them avoid obesogenic behaviors. This study has a longitudinal RCT study design. The study will be conducted in the University of Kentucky Friendly Clinic (Clinica Amiga). Participants will be followed for six months after the intervention. At least one adult who agrees to participate will sign the informed consent and HIPAA authorization, including the children's assent form. We anticipate that recruitment would include non-English speaking subjects due to Latinx self-identity, and for this reason, consent will be obtained in Spanish. The PIs, Co-I, and RP are fluent in English/Spanish and familiar with Latinx culture. Randomization: Randomization occurs after the baseline interview. Researchers will prepare ordered envelopes that contain the treatment assignments, one set for each stratum. Within each stratum, the treatment assignments will be placed in blocks of 10 (i.e., five assignments to each of the treatment conditions). To minimize attrition, complete contact information from participants will be collected and they will be asked to provide the phone number of two individuals who will know how to contact them in the future. Escalating incentives will be provided during data collection encounters to maximize retention. Reminders will be sent monthly for the duration of the study. Data Collection: Data will be collected by the trained RS who are blind to the study conditions at the following times: T1-baseline at recruitment-pre-intervention and randomization, T2-two weeks after the intervention, T3-Three months after the intervention, and T4-Six months after the intervention.
ETHNOPHARMACOLOGICAL RELEVANCE: In the Tibetan region of China, Thlaspi arvense L. is utilized for the prevention and treatment of hyperuricemia (HUA). Thlaspi arvense has been shown to lower uric acid levels in HUA rats in preliminary studies. However, the active components and mechanisms that account for its therapeutic effects remain elusive.
AIM OF STUDY: Network pharmacology, ultra-performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS), mRNA-sequencing, and quantitative reverse transcription PCR (RT-PCR) were used to investigate the active ingredients of Thlaspi arvense against HUA in rats and elucidate the underlying mechanisms in this study.
MATERIALS AND METHODS: A HUA rat model was established by a combination of intraperitoneal injection of potassium oxonate and intragastric administration of yeast extract. In the control and model groups, gastric gavage was performed to administer a normal saline solution, 4.5 mg kg-1 benzbromarone in the positive drug group, and 3.5 g kg-1Thlaspi arvense in the Thlaspi arvense group. After which network pharmacology and UPLC-Q-TOF-MS were employed to explore the active ingredients underlying the lowering of uric acid in Thlaspi arvense. In addition, mRNA-sequencing, network pharmacology and RT-PCR were applied to uncover Thlaspi arvense's mechanism of uric acid reduction.
RESULTS: The results showed that a two-week administration of the effective constituents of Thlaspi arvense led to a significant improvement in HUA rats, including lower serum levels of uric acid (UA), xanthine oxidase (XOD), creatinine (CREA), carbamide (UREA), aspartate aminotransferase (AST), alanine transaminase (ALT), and liver tissue activities of XOD, ADA, super (MDA). A network pharmacological analysis revealed 40 active compounds, including organic acids and flavonoids, that act on HUA therapeutic targets. These targets primarily focus on pathways related to uric acid metabolism modulation, such as XOD, SLC22A12, ABCG2, SLC22A8, and others, reducing HUA. The analysis of mRNA-sequencing as well as RT-PCR data from renal tissue demonstrated that the targets modulating uric acid metabolism were SLC22A8, SLC12A1, and SLC16A7.
CONCLUSION: In summary, organic acids and flavonoids may be the active components in Thlaspi arvense that alleviate HUA. The principal mechanisms are as follows: inhibition of XOD activity in the serum to reduce uric acid production, regulation of renal reabsorption and secretion of uric acid to increase uric acid excretion, and alleviation of oxidative stress reaction to decrease systemic damage and, eventually, treatment of HUA.
The present invention combines the modern pharmacology of traditional Chinese medicines to study cardiovascular diseases and cerebrovascular diseases and takes debility as the basis. Pathogenesis characteristics of silt heat are also taken into account. A health care medicinal wine prepared by pharmaceutical combination is provided through theories of supplementing qi, nourishing yin, promoting blood circulation, removing obstruction in collaterals, clearing away the heart fire and tranquillizing, and the name of the commodity is 'Shengde liquor'. The present invention can reach the effects of promoting blood circulation, nourishing heart qi, preventing diseases, treating diseases and health care. The health care medicinal wine is formed by soaking the comprises effective components of the following weight proportion: 100 portion of ganoderma, 50 portions of ginkgo leaves, 80 portions of hairy holly roots, 20 portions of dogwood fruits, 30 portions of ginseng, 10 portions of cooked date kernels, 20 portions of Chinese yams, 50 portions of Chinese dates, 20 portions of chrysanthemums, 20 portions of white atractylodes rhizomes, 20 portions of red sage roots, 20 portions of prepared rhizomes of rehmannia, 30 portions of amomun fruits, 20 portions of tuckahoe, 20 portions of eucommia barks, 20 portions of pawpaws, 20 portions of Chinese wolfberry fruits, 10 portions of licorice roots, 30 portions of longan aril, 20 portions of prepared fleece flower roots, 20 portions of decumbent corydalis tubers, 20 portions of fragrant solomonseal rhizomes and 20 portions of cinnamon. Main pharmacodynamics experiments prove that the present invention can enhance the level of myocardial ischemia mouse serum caused of pituitrin, and the level of myocardium SOD, reduce the contents of serum and myocardium MDA, and improve myocardial ischemia caused by pituitrin.
The invention provides a compound Chinese medicinal granule for treatment of chicken indigestion and a preparation method thereof. The granule consists of the following 7 drugs: pinellia ternata, scutellaria baicalensis, ginseng, dried ginger, licorice (broiled), coptis chinensis, and jujubes. Effective components of the drugs are extracted respectively according to certain technical method. The method is characterized by increasing the pinellia ternata dose and reducing the toxicity to 1/2000 by certain preparation process. The whole compound is rigorous, the process is simple and reasonable, and the prepared granule is convenient to use and has a long period of validity. Thus, the prescription granule has better curative effect and wider indications, and realizes the purposes of safety, effective, stable and convenient use on pets.